Keep cool in the crisis with administration in When MH strikes,
LESS THAN 1 MINUTE
ADVANCING THE STANDARD IN MALIGNANT HYPERTHERMIA (MH) TREATMENT.
RYANODEX® (dantrolene sodium) for injectable suspension is changing how MH is treated.
• Less time for reconstitution and administration – Less than 1 minute for a loading dose (2.5 mg/kg) of dantrolene sodium in an MH crisis1,2
• Less risk of complications with less fl uid – Over 99% less sterile water for injection than other dantrolene sodium IV treatments3-5
• Less effort to stay cool in an MH crisis – 1 vial provides a loading dose for patients up to 100 kg and can be administered by 1 healthcare professional (eg, an anesthesia provider)1,3
To request that RYANODEX® be stocked in your institution or obtain ordering information, visit
RYANODEX.com/asca or call 855.318.2170.
References: 1. Data on fi le. Eagle Pharmaceuticals, Inc. 2. Managing an MH crisis. Malignant Hyperthermia Association of the United States website.
http://www.mhaus.org/healthcareprofessionals/managing-a-crisis. Accessed June 18, 2014. 3. RYANODEX [package insert]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; 2014. 4. Dantrium Intravenous [package insert]. Rochester, MI: JHP Pharmaceuticals, LLC; 2008. 5. Revonto [package insert]. Louisville, KY: US WorldMeds, LLC; 2011.
Please see Brief Summary of full Prescribing Information on the following page.
© 2014 Eagle Pharmaceuticals, Inc. All rights reserved. 50 Tice Blvd, Suite 315 Woodcliff Lake, NJ 07677 (201) 326-5300 RYN14-0027-01 10/2014
INDICATION RYANODEX®
(dantrolene sodium) for injectable suspension
is indicated for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia in patients at high risk.
IMPORTANT SAFETY INFORMATION RYANODEX®
• Discontinuing triggering anesthetic agents
• Increasing oxygen
• Managing the metabolic acidosis
is not a substitute for appropriate supportive
measures in the treatment of malignant hyperthermia (MH), including:
• Instituting cooling when necessary
• Administering diuretics to prevent late kidney injury due to myoglobinuria (the amount of mannitol in RYANODEX®
is insuffi cient to maintain diuresis)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46
